HIGHLIGHTS
- who: Roberto Alfonso-Dunn from the Carlos III Health Institute (ISCIII), Spain University of Kentucky, United States have published the paper: Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies, in the Journal: (JOURNAL)
- what: To determine antibody levels generated in the study cohorts, the authors focused on antibody binding to the receptor binding domain (RBD) from subunit 1 of the CoV-2 spike_protein. The bold, continuous line indicates the regression line and the vertical dotted line highlights limit of sensitivity for antibody titers. those . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.